Контроль над бронхиальной астмой и возможности его достижения

1. Чучалин А.Г. Респираторная медицина: Руководство. М.: ГЭОТАР-Медиа; 2007; т. 1–2.

2. Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA), пересмотр 2006 г.: Пер.с англ. М.: Атмосфера; 2007.

3. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004; 59: 469–478.

4. Dusser D. et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendation. Allergy 2007; 62: 591–604.

5. Ward C., Pais M., Bish R. et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309–316.

6. Bateman E.D., Boushey H., Bousquet J. et al. Can guidelinedefned asthma control be achieved? The Gaining Optimal Asthma controL study. Am. J. Respir. Crit. Care Med 2004; 170: 836–844.

7. Bateman E.D., Clark T.J.H., Frith L. et al. Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the GOAL study. J. Asthma 2007; 44: 667–673.

8. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur. Respir. J. 2002; 19: 182–191.

9. Ind P.W., Dal Negro R., Colman N.C. et al. Addition of salmeterol to fluticasone propionate treatment in moderate to severe asthma. Respir. Med. 2003, 97: 555–562.

10. Matz J., Emmett A., Rickard K., Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J. Allergy Clin. Immunol. 2001; 107 (suppl. 5): 783–789.

11. Houghton C.M., Lawson N., Borrill Z.L. et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respir. Res. 2007, 8: 52.

12. Martin R.J. Therapeutic significance of distal airway inflammation in asthma. J. Allergy Clin. Immunol. 2002; 109 (suppl. 2): S447–S460.

13. Currie G.P., Stenback S., Lipworth B.J. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br. J. Clin. Pharmacol. 2003; 56: 11–17.

14. Britton M.G., Earnshaw J.S., Palmer J.B.D. A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur. Respir. J. 1992; 5: 1062–1067.

15. Lundback B., Rawlinson D.W., Palmer J.B.D. Twelve month comparison of salmeterol with salbutamol as dry powder formulations in asthmatic patients. Thorax 1993, 48: 148–153.

16. Lundback B. et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir. Med. 2006; 100: 2–10.

17. Rojas R.A., Paluga I., Goldfrad C.H. et al. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. J. Asthma 2007; 44: 437–441.

18. Barnes N.C., Jasques L., Goldfrad C., Bateman E.D. Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100 mcg bd versus fluticasone propionate 100 mcg bd alone in patients with persisitent asthma: integrated analysis of four randomized trials. Respir. Med. 2007; 101: 2358–2365.

19. Pedersen S.E., Bateman E.D., Bousquet J. et al. Determinates of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J. Allergy Clin. Immunol. 2007; 120: 1036–1042.